的二次代谢物可以改善阿尔茨海默氏症吗? 一个计算灵活的对接调查
Ashaimaa Y Moussa1, Abdullah R Alanzi2, Muhammad Riaz3
1Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
Journal of medicinal food
|August 9, 2024
概括
分子建模确定了强大的化合物用于阿尔茨海默病药物发现. 这些化合物与BACE1和ACHE等关键酶具有有前途的相互作用,指导未来的体外和体内研究.
科学领域:
- 计算化学和药物发现.
- 神经科学和神经退行性疾病研究.
- 自然产品的化学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,没有有效的治疗方法.
- 分子建模为识别潜在治疗剂提供了具有成本效益的战略.
- 衍生化合物是新型化学支架的丰富来源.
研究的目的:
- 为了计算衍生化合物对阿尔茨海默氏病点的潜在活性进行选.
- 评估选择化合物的结合亲和力和相互作用与关键酶参与AD的发病.
- 为指导选择有前途的化合物用于随后的体外和体内验证.
主要方法:
- 使用Qikprop和发现工作室的毒性和ADMET研究.
- 刚性和灵活的分子对接,包括诱导适合对接 (IFD),在BACE1和ACHE酶上.
- 使用Maestro和Cresset Flare的高精度分子对接,与标准药物相比.
- 对分子相互作用,结合能,Glide XP分数,RMSD值和分子动力学模拟的分析.
主要成果:
- 超过45种化合物被审查,其中几个被认为是有前途的.
- 狄氏甲基纳醇A和人体素I显示与BACE1 (4ey7) 结合部位的结合一致.
- 伊诺芬醇A,加诺米辛和福尼辛对ACHE (4dju) 结合部位表现出有利的结合,类似于本地配体.
- 分子动力学模拟支持对接结果,预测显著的体外疗效.
结论:
- 分子建模,特别是IFD,对于神经退行性疾病的早期药物发现至关重要.
- 精选的化合物显示出强大的潜力作为ACHE和BACE1.1的抑制剂.
- 这些通过计算识别的化合物需要在阿尔茨海默病治疗的临床前和临床研究中进一步调查.
更多相关视频
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
11.8K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.5K
相关概念视频
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
